Calcium-Phosphorus Regulation Therapy on Heart Valve Disease

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 196 participants.

Also called NCT06660524

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 196 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT06660524
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT06660524. Randomized; no masking; primary purpose treatment. Start 2024-03-01 (actual); primary completion 2025-06 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Calcium-Phosphorus Regulation Therapy on Heart Valve Disease
Condition
Degenerative Heart Valve Disease
Condition
Heart Valve Calcification
Condition
Calcium-Phosphorus Metabolism Disorders
Intervention (Drug)
Sevelamer
Intervention (Drug)
Calcium carbonate
Lead sponsor
China National Center for Cardiovascular Diseases (class: other government)

Record details

Record id
cardio:ct-nct06660524
Content hash
4324989369e9621689f0ff7dd40788da7d858f01084671b410ad77a7296fe7f3